Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.95
AFFX's Cash to Debt is ranked lower than
66% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. AFFX: 0.95 )
Ranked among companies with meaningful Cash to Debt only.
AFFX' s 10-Year Cash to Debt Range
Min: 0.15  Med: 1.22 Max: No Debt
Current: 0.95
Equity to Asset 0.62
AFFX's Equity to Asset is ranked higher than
54% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. AFFX: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
AFFX' s 10-Year Equity to Asset Range
Min: 0.19  Med: 0.54 Max: 0.95
Current: 0.62
0.19
0.95
Interest Coverage 0.33
AFFX's Interest Coverage is ranked lower than
100% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. AFFX: 0.33 )
Ranked among companies with meaningful Interest Coverage only.
AFFX' s 10-Year Interest Coverage Range
Min: 0.27  Med: 1.45 Max: 37.16
Current: 0.33
0.27
37.16
F-Score: 8
Z-Score: 2.17
M-Score: -2.68
WACC vs ROIC
0.20%
7.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 7.53
AFFX's Operating margin (%) is ranked higher than
68% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. AFFX: 7.53 )
Ranked among companies with meaningful Operating margin (%) only.
AFFX' s 10-Year Operating margin (%) Range
Min: -254.35  Med: -8.18 Max: 17.26
Current: 7.53
-254.35
17.26
Net-margin (%) 5.29
AFFX's Net-margin (%) is ranked higher than
68% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.06 vs. AFFX: 5.29 )
Ranked among companies with meaningful Net-margin (%) only.
AFFX' s 10-Year Net-margin (%) Range
Min: -232.61  Med: -6.13 Max: 17.9
Current: 5.29
-232.61
17.9
ROE (%) 6.55
AFFX's ROE (%) is ranked higher than
64% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.27 vs. AFFX: 6.55 )
Ranked among companies with meaningful ROE (%) only.
AFFX' s 10-Year ROE (%) Range
Min: -68.27  Med: -5.95 Max: 22.99
Current: 6.55
-68.27
22.99
ROA (%) 3.81
AFFX's ROA (%) is ranked higher than
68% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.44 vs. AFFX: 3.81 )
Ranked among companies with meaningful ROA (%) only.
AFFX' s 10-Year ROA (%) Range
Min: -33.34  Med: -3.11 Max: 10.32
Current: 3.81
-33.34
10.32
ROC (Joel Greenblatt) (%) 34.33
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. AFFX: 34.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AFFX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -120.45  Med: -9.36 Max: 84.04
Current: 34.33
-120.45
84.04
Revenue Growth (3Y)(%) 8.20
AFFX's Revenue Growth (3Y)(%) is ranked higher than
63% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. AFFX: 8.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AFFX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -33.6  Med: 6.00 Max: 102.9
Current: 8.2
-33.6
102.9
EBITDA Growth (3Y)(%) 52.40
AFFX's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. AFFX: 52.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AFFX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -24.4  Med: 0.00 Max: 52.4
Current: 52.4
-24.4
52.4
EPS Growth (3Y)(%) -50.00
AFFX's EPS Growth (3Y)(%) is ranked lower than
88% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. AFFX: -50.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AFFX' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3  Med: 3.50 Max: 25.1
Current: -50
-55.3
25.1
» AFFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

AFFX Guru Trades in Q3 2014

Jim Simons 576,885 sh (+190.94%)
Paul Tudor Jones 29,500 sh (+44.61%)
Chuck Royce 90,000 sh (unchged)
PRIMECAP Management 10,559,240 sh (unchged)
Murray Stahl 104,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q4 2014

AFFX Guru Trades in Q4 2014

Joel Greenblatt 38,181 sh (New)
Paul Tudor Jones 30,745 sh (+4.22%)
PRIMECAP Management 10,940,040 sh (+3.61%)
Murray Stahl 104,000 sh (unchged)
Jim Simons 282,620 sh (-51.01%)
Chuck Royce 4,000 sh (-95.56%)
» More
Q1 2015

AFFX Guru Trades in Q1 2015

Jim Simons 1,346,823 sh (+376.55%)
Paul Tudor Jones 38,200 sh (+24.25%)
PRIMECAP Management 11,037,040 sh (+0.89%)
Chuck Royce 4,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q2 2015

AFFX Guru Trades in Q2 2015

Jim Simons 2,153,623 sh (+59.90%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 4,000 sh (unchged)
PRIMECAP Management 11,014,740 sh (-0.20%)
Paul Tudor Jones 30,700 sh (-19.63%)
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 39.50
AFFX's P/E(ttm) is ranked lower than
64% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.70 vs. AFFX: 39.50 )
Ranked among companies with meaningful P/E(ttm) only.
AFFX' s 10-Year P/E(ttm) Range
Min: 11.36  Med: 51.76 Max: 971
Current: 39.5
11.36
971
Forward P/E 22.17
AFFX's Forward P/E is ranked lower than
63% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.33 vs. AFFX: 22.17 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 41.20
AFFX's PE(NRI) is ranked lower than
66% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. AFFX: 41.20 )
Ranked among companies with meaningful PE(NRI) only.
AFFX' s 10-Year PE(NRI) Range
Min: 11.71  Med: 53.51 Max: 971
Current: 41.2
11.71
971
P/B 2.26
AFFX's P/B is ranked higher than
67% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. AFFX: 2.26 )
Ranked among companies with meaningful P/B only.
AFFX' s 10-Year P/B Range
Min: 0.24  Med: 1.96 Max: 11.78
Current: 2.26
0.24
11.78
P/S 2.14
AFFX's P/S is ranked higher than
62% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. AFFX: 2.14 )
Ranked among companies with meaningful P/S only.
AFFX' s 10-Year P/S Range
Min: 0.38  Med: 1.76 Max: 11.22
Current: 2.14
0.38
11.22
PFCF 20.61
AFFX's PFCF is ranked higher than
69% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.00 vs. AFFX: 20.61 )
Ranked among companies with meaningful PFCF only.
AFFX' s 10-Year PFCF Range
Min: 1.89  Med: 16.70 Max: 1220.5
Current: 20.61
1.89
1220.5
POCF 16.07
AFFX's POCF is ranked higher than
69% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.49 vs. AFFX: 16.07 )
Ranked among companies with meaningful POCF only.
AFFX' s 10-Year POCF Range
Min: 1.64  Med: 20.31 Max: 2657
Current: 16.07
1.64
2657
EV-to-EBIT 29.93
AFFX's EV-to-EBIT is ranked lower than
67% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.91 vs. AFFX: 29.93 )
Ranked among companies with meaningful EV-to-EBIT only.
AFFX' s 10-Year EV-to-EBIT Range
Min: -2863  Med: -7.35 Max: 670
Current: 29.93
-2863
670
Current Ratio 4.12
AFFX's Current Ratio is ranked higher than
70% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. AFFX: 4.12 )
Ranked among companies with meaningful Current Ratio only.
AFFX' s 10-Year Current Ratio Range
Min: 1.52  Med: 5.27 Max: 23.52
Current: 4.12
1.52
23.52
Quick Ratio 3.19
AFFX's Quick Ratio is ranked higher than
65% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. AFFX: 3.19 )
Ranked among companies with meaningful Quick Ratio only.
AFFX' s 10-Year Quick Ratio Range
Min: 1.25  Med: 4.96 Max: 23.21
Current: 3.19
1.25
23.21
Days Inventory 140.24
AFFX's Days Inventory is ranked lower than
79% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.06 vs. AFFX: 140.24 )
Ranked among companies with meaningful Days Inventory only.
AFFX' s 10-Year Days Inventory Range
Min: 77.31  Med: 116.75 Max: 2372.5
Current: 140.24
77.31
2372.5
Days Sales Outstanding 53.76
AFFX's Days Sales Outstanding is ranked higher than
61% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. AFFX: 53.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
AFFX' s 10-Year Days Sales Outstanding Range
Min: 49.04  Med: 76.35 Max: 114.29
Current: 53.76
49.04
114.29

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 21.07
AFFX's Price/Net Current Asset Value is ranked lower than
81% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.66 vs. AFFX: 21.07 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AFFX' s 10-Year Price/Net Current Asset Value Range
Min: 1.9  Med: 12.64 Max: 419.8
Current: 21.07
1.9
419.8
Price/Tangible Book 10.65
AFFX's Price/Tangible Book is ranked lower than
81% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.24 vs. AFFX: 10.65 )
Ranked among companies with meaningful Price/Tangible Book only.
AFFX' s 10-Year Price/Tangible Book Range
Min: 0.87  Med: 9.28 Max: 75.92
Current: 10.65
0.87
75.92
Price/Projected FCF 1.86
AFFX's Price/Projected FCF is ranked higher than
55% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.94 vs. AFFX: 1.86 )
Ranked among companies with meaningful Price/Projected FCF only.
AFFX' s 10-Year Price/Projected FCF Range
Min: 0.42  Med: 1.47 Max: 219.36
Current: 1.86
0.42
219.36
Price/Median PS Value 1.22
AFFX's Price/Median PS Value is ranked lower than
70% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. AFFX: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
AFFX' s 10-Year Price/Median PS Value Range
Min: 0.31  Med: 2.70 Max: 38.33
Current: 1.22
0.31
38.33
Price/Graham Number 4.37
AFFX's Price/Graham Number is ranked lower than
78% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. AFFX: 4.37 )
Ranked among companies with meaningful Price/Graham Number only.
AFFX' s 10-Year Price/Graham Number Range
Min: 0.94  Med: 5.34 Max: 24.41
Current: 4.37
0.94
24.41
Earnings Yield (Greenblatt) (%) 3.30
AFFX's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. AFFX: 3.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AFFX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 2.00 Max: 387
Current: 3.3
0.1
387
Forward Rate of Return (Yacktman) (%) -7.19
AFFX's Forward Rate of Return (Yacktman) (%) is ranked lower than
89% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. AFFX: -7.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AFFX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -19.7  Med: 1.80 Max: 12.2
Current: -7.19
-19.7
12.2

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 359 374 389
EPS($) 0.39 0.43 0.47
EPS without NRI($) 0.39 0.43 0.47

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AFF.Germany,
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
» More Articles for AFFX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: PXLW, NGPC, MS, CHMT, AFFX Aug 15 2011 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares Nov 19 2010 
Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares Aug 24 2010 
Weekly CFO Buys Highlight: AspenBio Pharma, Solarwinds, Affymetrix, Cascade Financial Corp., Bank of Jul 31 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Solarwinds Inc., PDL BioPharma, Autobytel Inc., Affymetrix May 08 2010 
Affymetrix Inc. Reports Operating Results (10-Q) May 06 2010 
Weekly CFO Buys Highlight: Ocean BioChem, Affymetrix, Richardson Electronics, First Defiance Financi May 02 2010 
Affymetrix Reports Fourth Quarter and Fiscal Year 2008 Results Jan 28 2009 
Affymetrix to Host Conference Call on January 28, 2009 to Announce Fourth Quarter and Fiscal 2008 Re Jan 27 2009 
Weekly CEO Buys Highlight: ScheringPlough Corp., Novellus Systems Inc., SeaBright Insurance Holdings May 01 2008 

More From Other Websites
Coverage initiated on Affymetrix by Cantor Fitzgerald Aug 27 2015
Affymetrix Reports New Employee Stock Grants Aug 21 2015
Affymetrix Reports New Employee Stock Grants Aug 21 2015
Lightning Round: It had a great run, and now it's over Aug 18 2015
Affymetrix Announces 2015 Tumor Profiling Grant Award Recipients to Support Translational Cancer... Aug 11 2015
Affymetrix Announces 2015 Tumor Profiling Grant Award Recipients to Support Translational Cancer... Aug 11 2015
AFFYMETRIX INC Financials Aug 07 2015
10-Q for Affymetrix, Inc. Aug 01 2015
AFFYMETRIX INC Files SEC form 10-Q, Quarterly Report Jul 30 2015
Affymetrix Tops Earnings, Revenues; Currency Woes to Stay - Analyst Blog Jul 30 2015
Edited Transcript of AFFX earnings conference call or presentation 29-Jul-15 9:00pm GMT Jul 30 2015
Affymetrix tops Street 2Q forecasts Jul 29 2015
Affymetrix tops Street 2Q forecasts Jul 29 2015
Affymetrix Inc Earnings Call scheduled for 5:00 pm ET today Jul 29 2015
AFFYMETRIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 29 2015
Affymetrix Reports Second Quarter 2015 Operating Results Jul 29 2015
Cytox and Affymetrix form strategic partnership to develop and commercialize blood-based genetic... Jul 23 2015
Affymetrix's Axiom Genotyping Platform Selected by Cytox - Analyst Blog Jul 21 2015
Cytox and Affymetrix Form Strategic Partnership to Develop and Commercialize Blood-Based Genetic... Jul 20 2015
Genotyping Begins on NIDA’s Biorepository of Over 50,000 Samples – Affymetrix, BioRealm, and... Jul 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK